PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
1.75%
Revenue growth above 1.5x 3088.T's 1.16%. David Dodd would confirm if the firm has a unique advantage driving sales higher.
1.77%
Gross profit growth similar to 3088.T's 1.62%. Walter Schloss would assume both firms track common industry trends.
4.04%
EBIT growth below 50% of 3088.T's 13.79%. Michael Burry would suspect deeper competitive or cost structure issues.
15.41%
Operating income growth above 1.5x 3088.T's 5.42%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
13.61%
Net income growth at 50-75% of 3088.T's 18.89%. Martin Whitman would question fundamental disadvantages in expenses or demand.
13.59%
EPS growth at 50-75% of 3088.T's 19.09%. Martin Whitman would suspect a lag in operational efficiency or a higher share count.
13.59%
Diluted EPS growth at 50-75% of 3088.T's 19.07%. Martin Whitman would question if share issuance or modest net income gains hamper progress.
0.02%
Slight or no buybacks while 3088.T is reducing shares. John Neff might see a missed opportunity if the company’s stock is cheap.
0.02%
Slight or no buyback while 3088.T is reducing diluted shares. John Neff might consider the competitor’s approach more shareholder-friendly.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Negative OCF growth while 3088.T is at 0.76%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-100.00%
Negative FCF growth while 3088.T is at 0.76%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
160.73%
10Y revenue/share CAGR 1.25-1.5x 3088.T's 111.01%. Bruce Berkowitz would investigate brand strength or geographical expansion fueling growth.
56.92%
5Y revenue/share CAGR at 50-75% of 3088.T's 77.67%. Martin Whitman would worry about a lagging mid-term growth trajectory.
34.46%
3Y revenue/share CAGR under 50% of 3088.T's 77.90%. Michael Burry might see a serious short-term decline in relevance vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
138.65%
Below 50% of 3088.T's 325.01%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
37.21%
Below 50% of 3088.T's 125.19%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
-32.24%
Negative 3Y CAGR while 3088.T is 138.80%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
331.44%
10Y equity/share CAGR 1.25-1.5x 3088.T's 245.30%. Bruce Berkowitz would see if strong ROE or conservative payout policy fosters faster book value growth.
86.25%
5Y equity/share CAGR at 50-75% of 3088.T's 148.25%. Martin Whitman would question a shortfall in capital accumulation vs. the competitor.
35.83%
Below 50% of 3088.T's 108.16%. Michael Burry suspects a serious short-term disadvantage in building book value.
No Data
No Data available this quarter, please select a different quarter.
166.67%
Dividend/share CAGR of 166.67% while 3088.T is zero. Bruce Berkowitz sees a minor advantage in stepping up distributions, even modestly.
No Data
No Data available this quarter, please select a different quarter.
9.04%
AR growth well above 3088.T's 10.90%. Michael Burry fears inflated revenue or higher default risk in the near future.
-3.29%
Inventory is declining while 3088.T stands at 2.46%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
-1.36%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
1.52%
BV/share growth above 1.5x 3088.T's 0.63%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.
-6.02%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
No Data
No Data available this quarter, please select a different quarter.
-0.62%
We cut SG&A while 3088.T invests at 0.52%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.